The Pharmaceutical Industry and the Controlled Substances Act – A Distinct Breed of MonitorshipReprinted from: Global Investigations Review | June 9, 2020
Cadwalader's Jodi Avergun, Todd Blanche and Christian Larson provide insights into the practice of imposing monitorships on pharmaceutical companies that are settling alleged or admitted violations of the Controlled Substances Act for Global Investigations Review.
To read, click here.
The above is an extract from the second edition of "The Guide to Monitorships" published by Global Investigations Review. The whole publication is available here.